Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR) T cell therapy has revolutionized B cell malignancy treatment.
• Relapse after CAR T therapy, often due to CD19 antigen loss, remains a significant clinical challenge.
• Understanding the mechanisms of CD19 loss and identifying at-risk patients are crucial.

Purpose of the Study:

• To explore strategies for overcoming antigen loss in CAR T cell therapy for B cell malignancies.
• To evaluate the potential of multispecific CARs targeting multiple antigens to prevent relapse.
• To assess the efficacy and safety of bispecific CAR constructs in preclinical and early clinical settings.

Main Methods:

• Preclinical studies of CD19/20 and CD19/22 bispecific CARs.
• Phase I clinical trials evaluating the safety and efficacy of these multispecific CARs.
• Analysis of relapse rates, particularly CD19-negative relapse, in patients treated with bispecific CARs.

Main Results:

• Bispecific CARs demonstrated cytotoxicity against CD19-negative cancer cells in preclinical models.
• Phase I trials indicated favorable safety and efficacy profiles for CD19/20 and CD19/22 CARs.
• Early data suggest a lower rate of CD19-negative relapse with multispecific CAR T cell therapy.

Conclusions:

• Multispecific CAR T cells show potential in preventing B cell lymphoma relapse by overcoming antigen escape.
• Further investigation is needed to determine optimal target selection, CAR construct design, and long-term remission potential.
• These findings support the continued development of multispecific CAR T cell therapies for hematologic malignancies.